{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-030094","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.007650+00:00","generated_at":"2026-06-06T04:45:38.370640+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sutro Biopharma adds $100M to at-the-market equity program via new shelf registration","bullets":["Filed prospectus supplement to 2023 Form S-3 shelf, increasing shares available under existing Sales Agreement with Jefferies by $100M.","Total remaining capacity as of Feb 9, 2024: $29.3M from prior shelf plus $100M new supplement = $129.3M.","Previously sold $70.7M under the 2021 shelf registration since April 2021.","Shares sold through Jefferies LLC as sales agent at prevailing market prices.","Legal opinion on share validity filed as Exhibit 5.1 from Fenwick & West."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-030094","json":"https://secwatch.observer/filing/0001193125-24-030094.json","markdown":"https://secwatch.observer/filing/0001193125-24-030094.md","text":"https://secwatch.observer/filing/0001193125-24-030094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312524030094/0001193125-24-030094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312524030094/d737228d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:45:38.370640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}